Neuroinflammation

Overactivation of PARP-1 leads to chromatin remodeling, altered gene expression, and orchestration of inflammatory signaling cascades. This process can ultimately culminate in neuronal cell death and the perpetuation of the neuroinflammatory cycle. At Alfa Cytology, we provide PARP inhibitor development services for combating neuroinflammation.

PARP as a Therapeutic Target for Neuroinflammation

PARP-1 (poly (ADP-ribose) polymerase-1) plays a critical role in the pathogenesis of various neurological disorders, including stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, and spinal cord injury. Its overactivation leads to oxidative/nitrosative stress, DNA damage, and widespread inflammatory responses, ultimately resulting in neuronal dysfunction and cell death. Therefore, inhibiting PARP-1 is considered a promising therapeutic strategy to mitigate neuroinflammation, protect neurons, and improve functional recovery, with ongoing research into its clinical applications.

Fig. 1 PARP-mediated neuroinflammation in microglia. (Gutierrez-Quintana R., et al. 2022)

PARP Inhibitor Development for Neuroinflammation

The available preclinical evidence supports further investigation of repurposing clinically approved PARP inhibitors, like olaparib, as a novel therapeutic approach for the treatment of neuroinflammation.The study demonstrates that PARP inhibition in leukocytes can diminish their inflammatory potential and prevent BBB disruption, highlighting a potential therapeutic strategy for protecting the BBB in the context of neuroinflammation.

Our Services

At Alfa Cytology, our team of seasoned biological experts is dedicated to exploring the therapeutic potential of PARP inhibitors in mitigating neuroinflammation and associated neurological complications. Our state-of-the-art preclinical research facilities and expertise in cutting-edge in vitro and in vivo models enable us to conduct comprehensive investigations into the mechanisms by which PARP inhibition can confer neuroprotection and modulate the inflammatory landscape within the central nervous system.

Our comprehensive services include:

Our Featured Services

High-throughput Screening

We employ a rigorous screening process to identify the most promising PARP inhibitor compounds, evaluating their potency, selectivity, and ability to attenuate PARP-mediated neuroinflammatory pathways.

Mechanism of Action Studies

Our team of expert scientists delves deep into the underlying mechanisms by which PARP inhibition exerts its neuroprotective effects, shedding light on the complex interplay between PARP-1, oxidative stress, and inflammatory signaling cascades.

Preclinical Efficacy Studies

Using well-established animal models of neurological disorders, we assess the therapeutic efficacy of PARP inhibitors in reducing neuroinflammation, preserving neuronal integrity, and improving functional outcomes.

Pharmacokinetic and Safety Assessments

We rigorously evaluate the pharmacokinetic properties and safety profiles of PARP inhibitor candidates to ensure their suitability for clinical translation.

Alfa Cytology is committed to advancing the field of neuroinflammation research and driving the development of novel, mechanism-based therapies. To achieve this goal, we actively engage in collaborative efforts with leading academic institutions and pharmaceutical companies. For more information about our PARP inhibitor development program for neuroinflammation or to discuss potential collaborations, please don't hesitate to contact us.

For research use only. Not intended for any clinical use.